Louis Gaboury

Université de Montréal — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

44h-index8.3kcitations207works1.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

DNA Repair Mechanisms(26), S100 Proteins and Annexins(17), Breast Cancer Treatment Studies(11), Inflammatory mediators and NSAID effects(11), Galectins and Cancer Biology(10)

Publications204 total

Author Reply to Peer Reviews of The G protein-coupled receptor TBXA2R activates ERMs and promotes moesin-dependent motility and invasion of triple-negative breast cancer cells.
2025
Secretory Carcinoma of the Breast: Radiologic-Pathologic Correlation
Journal of Breast Imaging·2024· 2 citedOpen Access
A phase II trial to evaluate the epithelial-to-mesenchymal (EMT) inhibitor sotevtamab combined with docetaxel in patients with metastatic non-small cell lung cancer following failure of primary chemoimmunotherapy.
Journal of Clinical Oncology·2024· 1 cited
Silicone Particles in Capsules Around Breast Implants: An Investigation Into Currently Available Implants in North America
Aesthetic Surgery Journal·2023· 12 citedOpen Access
The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression
Cell Reports·2023· 8 citedOpen Access
Supplementary Figure 1 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 2 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Data from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplemental Data from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Data from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 1 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 3 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 4 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 3 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 2 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 4 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplementary Figure 5 from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Supplemental Data from PPARγ Ligand–induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers
2023Open Access
Data from Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
2023Open Access
page 1 of 11Next →

Frequent Co-authors

Mark Basik(7), Einas Yousef(6), Yves St‐Pierre(5), Pavel Hamet(4), Peter M. Siegel(4), Stéphanie Duhamel(4), Isabelle Trop(3), André Robidoux(3), Johanne Tremblay(3), Sylvain Meloche(3), Philippe P. Roux(3), Gilles Soulez(3), Morag Park(3), Muhammad Tahir(3), Prabir Pal(3), Gilles Durocher(3), L Villeneuve(3), Andrée-Anne Grosset(3), Claude Perreault(3), Sylvain Martel(2)